155 related articles for article (PubMed ID: 17642249)
21. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab.
Kalyoncu U; Karadag O; Akdogan A; Kisacik B; Erman M; Erguven S; Ertenli AI
Scand J Infect Dis; 2007; 39(5):475-8. PubMed ID: 17464877
[TBL] [Abstract][Full Text] [Related]
22. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
[TBL] [Abstract][Full Text] [Related]
23. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
[TBL] [Abstract][Full Text] [Related]
24. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.
Slifman NR; Gershon SK; Lee JH; Edwards ET; Braun MM
Arthritis Rheum; 2003 Feb; 48(2):319-24. PubMed ID: 12571839
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases.
Fujikawa K; Kawakami A; Hayashi T; Iwamoto N; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Ida H; Origuchi T; Eguchi K
Mod Rheumatol; 2010 Feb; 20(1):86-9. PubMed ID: 19812889
[TBL] [Abstract][Full Text] [Related]
26. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis.
Takeuchi T; Tatsuki Y; Nogami Y; Ishiguro N; Tanaka Y; Yamanaka H; Kamatani N; Harigai M; Ryu J; Inoue K; Kondo H; Inokuma S; Ochi T; Koike T
Ann Rheum Dis; 2008 Feb; 67(2):189-94. PubMed ID: 17644554
[TBL] [Abstract][Full Text] [Related]
27. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
28. Safety of biologic therapies--an update.
Keystone EC
J Rheumatol Suppl; 2005 Mar; 74():8-12. PubMed ID: 15742458
[TBL] [Abstract][Full Text] [Related]
29. Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan: a possible association between colonization and development of Pneumocystis jiroveci pneumonia during low-dose MTX therapy.
Mori S; Cho I; Ichiyasu H; Sugimoto M
Mod Rheumatol; 2008; 18(3):240-6. PubMed ID: 18306977
[TBL] [Abstract][Full Text] [Related]
30. [Pneumocystis pneumonia developed in two patients with rheumatoid arthritis during treatment of adalimumab].
Ikeuchi H; Umemoto A; Tsukida M; Sakurai N; Maeshima A; Kuroiwa T; Hiromura K; Nojima Y
Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(5):420-5. PubMed ID: 22041430
[TBL] [Abstract][Full Text] [Related]
31. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
Gaudin P
Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
[No Abstract] [Full Text] [Related]
32. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
Wolfe F; Michaud K
Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary infections in patients with rheumatoid arthritis who have received anti-TNF therapy.
Amano K
Intern Med; 2006; 45(17):991-2. PubMed ID: 17015997
[No Abstract] [Full Text] [Related]
34. Pneumocystis jirovecii pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept.
Arita Y; Taguchi H; Kobayashi M; Tono T; Ohsone Y; Okano Y
Mod Rheumatol; 2018 Nov; 28(6):1041-1043. PubMed ID: 27180974
[TBL] [Abstract][Full Text] [Related]
35. The Japanese experience with biologic therapies for rheumatoid arthritis.
Takeuchi T; Kameda H
Nat Rev Rheumatol; 2010 Nov; 6(11):644-52. PubMed ID: 20877307
[TBL] [Abstract][Full Text] [Related]
36. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy and adverse events of etanercept in patients with rheumatoid arthritis: reports of postmarketing surveillance in Japan].
Eguchi K
Nihon Rinsho; 2007 Jul; 65(7):1259-66. PubMed ID: 17642241
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis.
Imaizumi K; Sugishita M; Usui M; Kawabe T; Hashimoto N; Hasegawa Y
Intern Med; 2006; 45(10):685-8. PubMed ID: 16778341
[TBL] [Abstract][Full Text] [Related]
39. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
[TBL] [Abstract][Full Text] [Related]
40. [The pulmonological manifestations of rheumatoid arthritis].
Bernscherer G; Karabélyos C; Tarján Z
Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
